三鑫醫療(300453.SZ)監事餘珍珠完成減持 累計減持7.28萬股
格隆匯5月27日丨三鑫醫療(300453.SZ)公佈,公司於2020年3月24日在巨潮資訊網披露了《關於控股股東、實際控制人之一致行動人及部分董事、監事、高級管理人員股份減持計劃的預披露公告》,監事餘珍珠計劃通過集中競價方式減持公司股份累計不超過7.28萬股,即不超過公司總股本比例的0.03%,減持計劃自2020年4月16日至2020年10月13日期間實施。
2020年5月25日,公司收到餘珍珠出具的《關於股份減持計劃實施完成的告知函》,其減持計劃已實施完成,累計減持7.28萬股,當前持股比例0.0831%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.